Skip to main content Back to Top

Buprenorphine for Chronic Pain: Your Questions, Our Real-World Insights and Strategies for Success (CE)

October 5, 2026


ABOUT THIS PODCAST

In this episode, a panel of expert clinicians tackle some common and challenging unanswered questions surrounding the use of buprenorphine for chronic pain. Drawing from real-world practice, they explore strategies for initiation, risk mitigation, perioperative management, and formulation selection- while addressing practical barriers and off-label approaches. Listen in for evidenced-informed insights that bridge the gap between clinical uncertainty and confident prescribing.


SHOW NOTES

Introduction to Buprenorphine for Chronic Pain:

Perioperative Management of Buprenorphine:

  • Kohan L, Potru S, Barreveld AM, et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multi-society expert panel. Reg Anesth Pain Med. 2021 Oct;46(10):840-859. doi: 10.1136/rapm-2021-103007. Epub 2021 Aug 12. PMID: 34385292.

Barriers to Buprenorphine:

  • Sohn N, Lai B, Deyo-Svendsen M. Buprenorphine Prescribing Among Primary Care Clinicians for Chronic Pain and Opioid Use Disorder. J Am Board Fam Med. 2025 Sep-Oct;38(5):933-939. doi: 10.3122/jabfm.2025.250039R1. PMID: 41491568.

SPEAKERS

  • Amanda Benedetti, PharmD, BCGP, BCPMP
    Supervisor, Pharmacy Specialist, MetroHealth
  • Justin Kullgren, PharmD, FAAHPM, FPPCP
    Palliative Care Clinical Specialist, The Ohio State University Wexner Medical Center
  • Barbara Swift, PharmD, BCPS
    Postgraduate Year 2 Pain Management and Palliative Care Resident, Thomas H. Corey VA Medical Center

LISTEN ON


iTunes      Google            Spotify      TuneIn      iHeart Radio


The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.